Clinically, IMT cases benefit from routine molecular confirmation (e.g., ALK testing) to identify patients eligible for ALK inhibitors; resistance to first‐generation TKIs can occur and should be anticipated in management. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.